Search This Blog

Thursday, August 1, 2019

Higher medical costs take shine off Cigna second-quarter profit beat

Health insurer Cigna Corp raised its 2019 profit forecast on Thursday, helped by last year’s acquisition of pharmacy benefit manager Express Scripts, but medical costs in the second quarter were higher than expected and its shares fell slightly.

As health insurers face regulatory uncertainty amid political efforts to lower U.S. healthcare costs ahead of the 2020 presidential election, Cigna is hoping the $52 billion acquisition will help rein in its own costs.
In the quarter, however, Cigna’s medical care ratio – the percentage of premiums paid out for medical services – was 81.6%, above the 80.2% estimated analysts, according to Refinitiv data.
The company did report higher-than-expected earnings.
Bernstein analyst Lance Wilkes said that was mostly due to the pharmacy benefits business, while investors were likely focusing on the insurance side. “The higher valuation health insurance unit has some questions from medical costs and membership growth rate,” Wilkes said.
Medical costs have been an issue for the sector, with rivals like Centene Corp and Anthem Inc also missing expectations.
Cigna Chief Executive David Cordani said in an interview that the company’s costs are growing within expectations, and that several factors influenced the ratio.
He cited lowered premium rates in its individual insurance business, the suspension of an industry-wide insurance fee and higher costs from Express Scripts drug plans.
“Costs relative to any industry measure are extremely positive,” Cordani said.
As the 2020 presidential campaign heats up among potential Democratic challengers to U.S. President Donald Trump, proposals by some candidates for Medicare-For-All programs that would eliminate private insurance has cast a pall of uncertainty over the sector.
Republican Senator Charles Grassley and Democrat Ron Wyden are also pushing legislation that aims to cut $100 billion in costs to government healthcare programs.
Cordani said Cigna is engaged in Washington policy discussions and that it backs aspects of that bill, such as preventing patients from receiving surprising medical bills.
Cigna earned $4.19 per share excluding items for the quarter, beating Wall Street estimates of $3.74, according to Refinitiv IBES.
Cigna now expects 2019 adjusted income of $16.60 to $16.90 per share, up from its prior view of $16.25 to $16.65.
Adjusted revenue from the health services unit, which now includes Express Scripts pharmacy benefits, rose to $23.54 billion from $1.11 billion last year.
However, Cigna said earnings were lower than comparable results from Express Scripts’ second quarter in 2018.

Nektar up on breakthrough therapy tag

Nektar Therapeutics (NASDAQ:NKTR) is up 5% premarket on light volume in reaction to U.S. Breakthrough Therapy designation for bempegaldesleukin (NKTR-214), combined with Bristol-Myers Squibb’s (NYSE:BMY) Opdivo (nivolumab), for previously untreated patients with unresectable/metastatic melanoma.
Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.
A Phase 1/2 study, PIVOT-02, is ongoing.
Bempegaldesleukin is a CD122-preferential IL-2 pathway agonist designed to activate and proliferate certain cancer-killing immune cells.

Ultragenyx files U.S. application for rare dissease med

Ultragenyx (NASDAQ:RARE) has submitted a marketing application to the FDA seeking approval of triheptanoin (UX007) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), a group of inherited diseases in which the body is unable to metabolize long-chain fatty acids into energy. The indication has Rare Pediatric Disease Designation and Fast Track status.
UX007 is a purified pharmaceutical-grade form of triheptanoin, a triglyceride compound, that provides patients with medium-length odd-chain fatty acids which increase the intermediate substrates in the Krebs cycle, a key energy-generating process, which produces new glucose.

Genetic testers rally on insurance coverage for Myriad’s GeneSight

Genetic testing services providers are in the green after UnitedHealthcare instituted coverage for Myriad Genetics’ GeneSight test for major depressive disorder.
NeoGenomics (NEO +5.3%), Invitae (NVTA +0.9%), Fulgent Genetics (FLGT+12.8%)
Liquid biopsy services providers are enjoying a bump as well: Biocept (BIOC+1.9%), Bio-Techne (TECH +1.6%), Anixa Biosciences (ANIX +1.9%), OncoCyte (OCX +0.3%), Guardant Health (GH +1.9%)

Welltower target raised to $87 from $78 by Stifel

Maintains Buy

Vertex target upped to $230 from $217 by Piper

Maintains Overweight

United Therapeutics upped to Buy from Neutral by Ladenburg

Target to $106 from $103